Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip B Rawlins

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Scientific Reports|November 19, 2020
Complexities of a protonatable substrate in measurements of Hoechst 33342 transport by multidrug transporter LmrPBrendan M Swain, Dawei Guo, Himansha Singh, et al.
Journal of Medicinal Chemistry|May 24, 2023
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral DeliveryBenjamin C Whitehurst, Matthias R Bauer, Fredrik Edfeldt, et al.
Acta Crystallographica. Section D, Structural Biology|November 7, 2019
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1Jakub Luptak, Michal Bista, David Fisher, et al.
SLAS Discovery : Advancing Life Sciences R & D|December 8, 2020
Regenerable Biosensors for Small-Molecule Kinetic Characterization Using SPRAnders Gunnarsson, Christopher J Stubbs, Philip B Rawlins, et al.
The Biochemical Journal|October 29, 2020
A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of bindingAlexander Pflug, Marianne Schimpl, J Willem M Nissink, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding FragmentsClaire Shepherd, Sean Robinson, Alice Berizzi, et al.
Nature Chemical Biology|September 6, 2016
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chainGizem Akçay, Matthew A Belmonte, Brian Aquila, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2023
Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1David Hargreaves, Rodrigo J Carbajo, Michael S Bodnarchuk, et al.
Molecular Pharmacology|November 3, 2016
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation KineticsJ Daniel Hothersall, Dong Guo, Sunil Sarda, et al.
Nucleic Acids Research|January 29, 2021
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibitionTom E H Ogden, Ji-Chun Yang, Marianne Schimpl, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|November 19, 2020
Complexities of a protonatable substrate in measurements of Hoechst 33342 transport by multidrug transporter LmrPBrendan M Swain, Dawei Guo, Himansha Singh, et al.
Journal of Medicinal Chemistry|May 24, 2023
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral DeliveryBenjamin C Whitehurst, Matthias R Bauer, Fredrik Edfeldt, et al.
Acta Crystallographica. Section D, Structural Biology|November 7, 2019
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1Jakub Luptak, Michal Bista, David Fisher, et al.
SLAS Discovery : Advancing Life Sciences R & D|December 8, 2020
Regenerable Biosensors for Small-Molecule Kinetic Characterization Using SPRAnders Gunnarsson, Christopher J Stubbs, Philip B Rawlins, et al.
The Biochemical Journal|October 29, 2020
A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of bindingAlexander Pflug, Marianne Schimpl, J Willem M Nissink, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding FragmentsClaire Shepherd, Sean Robinson, Alice Berizzi, et al.
Nature Chemical Biology|September 6, 2016
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chainGizem Akçay, Matthew A Belmonte, Brian Aquila, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2023
Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1David Hargreaves, Rodrigo J Carbajo, Michael S Bodnarchuk, et al.
Molecular Pharmacology|November 3, 2016
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation KineticsJ Daniel Hothersall, Dong Guo, Sunil Sarda, et al.
Nucleic Acids Research|January 29, 2021
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibitionTom E H Ogden, Ji-Chun Yang, Marianne Schimpl, et al.
Pageof 3